Clinical Trial Update: Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL) [Phase 4]

View source ↗

Summary

A Phase 4 feasibility trial evaluating outpatient administration of blinatumomab in patients with minimal residual disease in B-cell precursor acute lymphoblast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• B-cell Precursor Acute Lymphoblastic Leukemia

Drugs mentioned

• Blinatumomab (Blincyto) (blinatumomab)

Snippet

Sponsor: Amgen | Conditions: B-precursor Acute Lymphoblastic Leukemia | Phase 4 | Status: TERMINATED | Results posted: 2025-05-18